Arjun V. Balar, MD, discusses some combinations currently being investigated in clinical trials for patients with bladder cancer.
Arjun V. Balar, MD, assistant professor in the Department of Medicine and director of the genitourinary medical oncology program at NYU Langone’s Perlmutter Cancer Center, discusses some combinations currently being investigated in clinical trials for patients with bladder cancer.
According to Balar, CTLA-4 blockade is being tested in combination with PD-1 blockade. The PD-1 pathway can play an important role in the treatment of bladder cancer, but it still needs to be tested further. This strategy is being investigated in both the CheckMate901 trial and the DANUBE trial.
FDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ
April 22nd 2024Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Read More